ADGEN
is
using
its
patented
technologies
as
an
umbrella under
which
it is
developping
a
series
of
chemical
analogs
based
on
the
structures
of
our
lead
lipid
mobiliser
protein,
as
well
as
novel
phospho-tau
inhibitor
compounds.
The
lead
optimization
process
will
result
in
the
production
of
new
chemical
entities
(NCEs)
for pre-clinical
research
programs.
The
final
candidates
which
are
bound
to
be
very
similar
in
structure
to our
key
lead
compounds
are designed
to
improve
on
their
current
regenerative
or
inhibiting
properties,
brain
penetration
and
cardiovascular
safety
profile.
The
production
of
potent
apoloproteins
modulators
that
stimulates
brain
reinnervation
will
be
used
to
slow
down
or,
possibly
stop
disease
progression,
but
more
importantly,
to
delay
the
onset
of
the
disease
in
people
who
are
not
symptomatic
but
carry
defective
“at
risk”
genes.
This
represents
a
clear
practical
and
achievable
mid-term
goal.
It
has
been
determined
that a
five
years
delay
in
the
onset
of
AD
could
translate
into
a
reduction
of
the
prevalence
of
Alzheimer's
disease
by
50%
in
occidental
countries
over
one
generation
and
in
a
reduction
of caring
cost
(direct
and
indirect)
in
excess
of
$1000 billions
worldwide (in
2018
dollars).
The
worldwide
market
for
such
a
drug
in
Alzheimer's
disease
alone
is
estimated
to
be
in
the
order of $12-15 billion per year.
ADGEN
has
identified
several
novel
genetic
and
proteomic
markers
for
age
of
onset,
disease
progression
and
response
to
standard
therapies
in
neurodegenerative
diseases
and
stroke,
all
linked
to
the
neuronal
remodeling
pathways.
The
ADGEN
team
has
also
discovered
protective
genetic
variants
that
attenuate
risk
and
affect
age
of
onset
while
providing
interesting
new
therapeutic
targets.
Dr.
Poirier’s
research
team
has
carried
out
extensive
pharmacogenomic
programs
the
past
three
decades
with
international
pharmas,
including
Warner-Lambert,
Pfizer,
Novartis,
Avantis,
Servier,
Astrazeneca
and
Bayer,
principallly
on cognitive
enhancer drugs
exhibiting
different
modes
of
action.
These
programs
have
been
associated
with
compound
drug
development
where
a
focus
was
built
around
individual
response
to
specific
therapeutic
agents.
This
approach
has
aided
the
interpretation
of
marginal
drug
effects
and
established
a
molecular
basis
for
efficacy
and
safety
in
several
experimental
compounds
in
randomised,
double-blind,
clinical
trials.
Dr.
Poirier
has
also
worked
with
the
genomic
team
at
Motorola
on
experimental
devices
designed
to
perform
low-cost
genetic
profiles
to
be
used
in
physician
offices,
an
emerging
market
for
both,
the
US
and
Europe.
The
initial
research-business
concept
holds
true
today,
but
in
a
broader
sense.
The
ADGEN
team
has
a
well
documented
and
proprietary
knowledge
of
mechanisms
for
neuronal
remodeling through the study of neuron degeneration caused by neurodegenerative diseases or trauma.
Services
© J. Poirier 2022
Français
Français
